Abstract
Mesothelioma is an uncommon tumor. It has a latency period of 20-40 years. The most important risk factor is asbestos exposure. Prognosis of mesothelioma is generally poor with high case-fatality rate, and research to improve the outcome of this disease is on-going worldwide. Due to its rarity, management by a multidisciplinary team with experience is recommended. Carefully selected patients may benefit from tri-modality (surgery, radiotherapy and chemotherapy) treatment. The management of pleural and peritoneal mesothelioma is summarized in this review. Recent advances in chemotherapy and biologic response modifiers are promising.
Keywords: Asbestos, epidemiology, treatment, Mesothelioma, tri-modality (surgery, radiotherapy and chemotherapy), pleural and peritoneal mesothelioma, malignant meosothelioma
Current Respiratory Medicine Reviews
Title: Mesothelioma - Epidemiology and Management
Volume: 7 Issue: 5
Author(s): Patricia Tai, Edward Yu, Avi Assouline and Kurian Joseph
Affiliation:
Keywords: Asbestos, epidemiology, treatment, Mesothelioma, tri-modality (surgery, radiotherapy and chemotherapy), pleural and peritoneal mesothelioma, malignant meosothelioma
Abstract: Mesothelioma is an uncommon tumor. It has a latency period of 20-40 years. The most important risk factor is asbestos exposure. Prognosis of mesothelioma is generally poor with high case-fatality rate, and research to improve the outcome of this disease is on-going worldwide. Due to its rarity, management by a multidisciplinary team with experience is recommended. Carefully selected patients may benefit from tri-modality (surgery, radiotherapy and chemotherapy) treatment. The management of pleural and peritoneal mesothelioma is summarized in this review. Recent advances in chemotherapy and biologic response modifiers are promising.
Export Options
About this article
Cite this article as:
Tai Patricia, Yu Edward, Assouline Avi and Joseph Kurian, Mesothelioma - Epidemiology and Management, Current Respiratory Medicine Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339811797189731
DOI https://dx.doi.org/10.2174/157339811797189731 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism Editorial: The Real Impact of Target Therapy in Cancer Patients: Between Hope and Reality
Current Cancer Drug Targets Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
Current Pharmaceutical Biotechnology The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma
Current Respiratory Medicine Reviews Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Tumor Treating Fields – Behind and Beyond Inhibiting the Cancer Cell Cycle
CNS & Neurological Disorders - Drug Targets Aerobic Nitroreduction by Flavoproteins: Enzyme Structure, Mechanisms and Role in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Altered Hyaluronan Biosynthesis and Cancer Progression: an Immunological Perspective
Mini-Reviews in Medicinal Chemistry Insulin-like Growth Factor-1 Receptor (IGF-1R) Kinase Inhibitors in Cancer Therapy: Advances and Perspectives
Current Pharmaceutical Design Recent Development and Application of Magnetic Nanoparticles for Cell Labeling and Imaging
Mini-Reviews in Medicinal Chemistry The Pharmacological Treatment of Cachexia
Current Drug Targets Meet Our Editorial Board Member:
Current Respiratory Medicine Reviews The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Impaired Expression and Function of Cancer-Related Enzymes by Anthocyans: An Update
Current Enzyme Inhibition Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis
Current Drug Targets Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?
Reviews on Recent Clinical Trials